Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OBI Pharma Inc.

www.obipharma.com

Latest From OBI Pharma Inc.

Siamab, BI Team To ‘Attack’ Potential Of Carbohydrate Antibodies In Cancer

With promising preclinical data for lead candidate ST1 in ovarian cancer, Siamab thinks therapeutics targeting tumor-associated carbohydrate antigens will offer potential in multiple solid tumor types.

Deals Platform Technologies

Deals Shaping The Medical Industry, July 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2017.

Deals BioPharmaceutical

Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts

While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.

Deals M & A

Argos And Agenus Trials Pile On Fresh Cancer Vaccine Disappointments

Argos mum on details surrounding Phase III failure of rocapuldencel-T in kidney cancer, while Agenus distances itself from failed Phase II glioblastoma study of Prophage G-200 as an investigator-sponsored trial with a challenging design.

Research & Development Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Alias(es)
  • Optimer Biotechnology Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Taiwan
  • Parent & Subsidiaries
  • OBI Pharma Inc.
  • Senior Management
  • Amy Huang, General Mgr.
    Cheng-Der Yu, PhD, CSO
    CT Wang, VP, Fin.
    Max Chan, COO
  • Contact Info
  • OBI Pharma Inc.
    Phone: 2 2655 8799
    Ste. W1907, 19F, 3 Park St.
    Nangang Dist.
    Taipei City, 11503
    Taiwan
Advertisement
Advertisement
UsernamePublicRestriction

Register